Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections.
Competitive Landscape:
Major players operating in the global antibacterial drugs market are Sanofi, Pfizer, Novartis, Merck & Co., Johnson & Johnson, Forest Laboratories, Eli Lilly and Company, Bayer AG, AstraZeneca plc, GlaxoSmithKline, Spero Therapeutics, VenatoRx Pharmaceuticals, NacuGen Therapeutics, Sichuan Pharmaceutical, Boston Pharmaceuticals, Debiopharm Group, Micurx Pharmaceutical Inc., Melinta Therapeutics, Entasis Therapeutics, R-Pharm Group, Theravance Biopharma, TenNor Therapeutics, Allecra Therapeutics GmbH, Kyorin Pharmaceutical Co., Iterum Therapeutics plc, Shionogi Inc, Wockhardt, and Bristol-Myers Squibb Company.
0